Premature babies to be immunised against winter virus
The injection will provide them "with a protective bubble" against RSV (respiratory syncytial virus) in time for the colder months, NHS medics said.
Most babies are protected via vaccination late in pregnancy, but babies born before 32 weeks are more vulnerable to life-threatening infections from the virus.
From late September, 9,000 babies and young children at risk across the UK will be offered a dose of the drug nirsevimab through the NHS.
RSV usually causes coughs and colds, but can make some children very ill with breathing problems, pneumonia and a lung infection called bronchiolitis.
According to NHS England, premature babies are three times more likely to go to hospital with RSV and are 10 times more likely to need intensive care compared with full-term babies.
Every year around 30,000 children in the UK aged under five need hospital care because of the virus, and around 30 don't survive.
The drug offers six months' protection in a single dose, and is more than 80% effective.
Neo-natal clinics will deliver the injection to premature babies. Families of vulnerable infants with heart or lung conditions or weakened immune systems will be advised by their medical teams how to get the jab before this winter.
"It will offer a long-lasting defence, helping to avoid unnecessary hospitalisations and serious illness, giving babies the best possible start in life and shielding them from harm," said Dr Claire Fuller, co-national medical director for NHS England.
Ill baby's mum urges pregnant women to get RSV jab
RSV jab could cut baby hospitalisations by 80% - study
Last year, a vaccination programme was launched in the UK to protect newborn babies and older people from RSV. Women who are at least 28 weeks' pregnant and people aged 75 to 79 are now offered that vaccine, called abrysvo.
The jab boosts a woman's immune system during pregnancy and protects babies in their first weeks of life.
But babies born prematurely, before 32 weeks, don't have time to build up protection from that vaccine before they're born.
They will be given nirsevimab instead.
Unlike a vaccine, which prompts the body to create antibodies and takes a few weeks to be effective, nirsevimab gives immediate protection from RSV infection.
Ceri Cox, 33, wanted her son, Harry, aged two, to be protected as much as possible against RSV. As a paediatric nurse, she has seen the damage it can do.
"I know quite a bit about the virus from working in a unit where we see a lot of children with RSV every year," she said.
"It's amazing that this immunisation will now be offered to young babies around the country. I hope we will see fewer little ones in our hospital this winter."
Harry took part in an international clinical trial of the immunisation at University Hospital Southampton.
Premature babies and high-risk infants in England, Scotland, Wales and Northern Ireland will benefit from the drug.
What are the symptoms of RSV?
They usually start within a few days of being infected.
Most people only get cold-like symptoms, such as:
a runny or blocked nose
a cough
sneezing
tiredness
a high temperature – signs include your back or chest feeling hotter than usual, sweatiness and shivering (chills)
Babies with RSV may also be irritable and feed less than usual.
If RSV leads to a more serious infection (such as pneumonia or bronchiolitis) it may also cause:
a cough that gets worse
shortness of breath
faster breathing or long gaps between breaths
difficulty feeding (in babies) or loss of appetite
noisy breathing (wheezing)
confusion (in older adults)
Source: NHS UK website
RSV jabs start for pregnant women and older people
Antibody jab approved for common winter virus RSV

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Speed of improvement in cancer survival rates ‘slowing', say experts
Progress in cancer survival rates in the UK has 'slowed down', experts have warned. The news comes as a study suggests survival between the most and least deadly types of the disease is wider than ever before. A national cancer plan was 'essential' to 'bring cancer survival trends back towards the best in the world', researchers said. The study, led by the London School of Hygiene and Tropical Medicine (LSHTM) and funded by Cancer Research UK, analysed long-term trends in the cancer survival index (CSI) for adults across England and Wales from 1971 to 2018. Using records from the National Disease Registration Service for England and the Welsh Cancer Intelligence and Surveillance Unit, experts estimated net survival for up to 10 years after diagnosis for around 10.8 million people. They found that in 2018, the CSI for all cancers combined a decade after diagnosis was 49.8%, higher than the CSI at one year for those diagnosed in 1971/72. Researchers hailed the figure as 'remarkable', but warned that the 'speed of improvement in survival has slowed down'. In the five years from 2000/01 to 2005/06, the 10-year CSI rose by 4%, from 41.2% to 45.2%. But between 2010/11 and 2015/16, the rise was 1.4%, from 47.9% to 49.3%. There were also major gaps in survival when it came to different cancer types. For example, 10-year survival for testicular cancer was 97%, compared with 4.3% for pancreatic cancer. Screening programmes had bolstered survival rates for cancers in the breast, bowel and cervix, according to Cancer Research UK. But survival for other types, such as stomach, lung and brain cancer, had increased by only a small amount in the past 50 years. Writing in the Lancet Regional Health – Europe, researchers warned this slowdown for individual cancers implied a 'system-wide challenge'. Michelle Mitchell, chief executive of Cancer Research UK, said: 'Thanks to research, most patients today are far more likely to survive their cancer than at any point in the past. 'But the reality is that this progress is slowing – and for some cancers, it never got going in the first place.' The Government launched a call for evidence to help shape a national cancer plan in February. The blueprint aims to outline actions to transform how the disease is treated in a bid to reduce deaths. Ms Mitchell said: 'The upcoming National Cancer Plan for England must include commitments to spot more cancers earlier, as well as backing research into new treatments so that each patient, regardless of their diagnosis, can hope for more moments with the people they love.' Michel Coleman, a professor of epidemiology and statistics at LSHTM, said: 'Since I began my career in cancer research, I've seen substantial increases in survival for most types of cancer. 'Our understanding of cancer biology has expanded, effective screening programmes have been introduced, and new treatments have been developed. Allowing this trend to stall will have devastating consequences. 'This study was only possible because of data on millions of patients from cancer registries in England and Wales. 'It's vital that the Government provides the political and financial support to ensure we maintain this crucial data. Without these, the Government will be flying blind on cancer control. 'The National Cancer Plan is a chance to improve NHS cancer pathways and reap the benefits of new research – the Government must take it.' Cancer Research UK is calling for the national cancer plan to slash waiting times for diagnosis and treatment, saying some patients face unacceptable delays. The plan should also improve early diagnosis of cancer, with plans to boost participation in existing screening programmes and a commitment to rolling out lung cancer screening fully in England by 2029. A Department of Health and Social Care spokesperson said: 'We are prioritising cancer care as we turn around more than a decade of neglect of our NHS. 'We're already seeing progress, with 95,000 more people having cancer diagnosed or ruled out within 28 days between July 2024 and May 2025, compared to the same period the previous year. 'The National Cancer Plan will set out how we will improve survival rates further and address the variation between different cancer types.'
Yahoo
an hour ago
- Yahoo
CPR questions to be added to driving theory test
Learner drivers are to be quizzed on their CPR skills in an update to the theory test. The Driver and Vehicle Standards Agency (DVSA) – which oversees driving tests in Britain – said motorists are often 'first on the scene' when someone suffers a cardiac arrest. Adding questions on CPR and defibrillators to the theory test from early next year means candidates will 'have a better understanding of the skills to use in an emergency', it added. More than 40,000 people in the UK suffer an out-of-hospital cardiac arrest each year, with fewer than one in 10 surviving. Research has found survival rates can be as high as 70% if CPR is given and a defibrillator used within three to five minutes of collapse. DVSA chief driving examiner Mark Winn said: 'Part of being a safe and responsible driver is knowing what to do in an emergency – how to step in and make a real, life-saving difference. 'Learning CPR and how to use a defibrillator is a very simple skill, and adding this into the official learning resource is a great way for DVSA to support the drive to raise awareness.' The push for the change was led by Professor Len Nokes – chair of the Save a Life Cymru scheme – whose 24-year-old daughter Claire died in 2017 from complications following a cardiac arrest. He said: 'When Claire, my daughter, had her cardiac arrest, some knowledge of CPR might have made a difference. 'I don't want any other family to go through this experience. 'All of us in this partnership hope that by making CPR and how to use a defibrillator part of the theory test, we will be able to significantly increase the number of people who have this life-saving awareness.' James Cant, chief executive of charity Resuscitation Council UK, said: 'By embedding these life-saving skills into such a widely-taken assessment, we can help ensure that more people, from all communities, gain the knowledge and confidence to act during a cardiac arrest.' Learners must pass the theory driving test before booking a practical test. Theory test candidates are required to get at least 43 out of 50 multiple-choice questions correct, covering areas such as road signs, traffic laws, vehicle safety and first aid. They must also pass a hazard perception video test. More than two million theory tests are taken each year, with a pass rate of about 45%.
Yahoo
an hour ago
- Yahoo
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN, August 12, 2025--(BUSINESS WIRE)--Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: "Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes." Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: "Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD." Elaine Mac Hale, Clinical Operations Director, added: "Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care." Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise. View source version on Contacts phyxiom@ or call Lewis Oakley or Kirsty Leighton on +44 20 3637 7310 Sign in to access your portfolio